PublicationsPancreatic changes in TNBS-induced colitis in mice.
Barthet M, Dubucquoy L, Garcia S, Gasmi M, Desreumaux P, Colombel JF, Grimaud JC, Iovanna J, Dagorn JC.
INSERM EMI 116 Marseille, Hôpital Nord. This email address is being protected from spambots. You need JavaScript enabled to view it.
Gastroenterol Clin Biol. 2003 Oct;27(10):895-900.
5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.
Cheng Y, Desreumaux P.
Institute of Liver Disease, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Pudong District, Shanghai 201203, China. This email address is being protected from spambots. You need JavaScript enabled to view it.
World J Gastroenterol. 2005 Jan 21;11(3):309-14.
The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD)
Rousseaux C, Desreumaux P.
Laboratoire de Physiopathologie des Maladies Inflammatoires Intestinales, INSERM E114, Hôpital Huriez, Service de Gastroentérologie, 1, place de Verdun, 59000 Lille.
J Soc Biol. 2006;200(2):121-31.
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma
Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P.
Institut National de la Santé et de la Recherche Medicale 0114, Physiopathologie des Maladies Inflammatoires Intestinales, CHU 59037 Lille, France.
J Exp Med. 2005 Apr 18;201(8):1205-15.
Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation.
Philippe D, Chakass D, Thuru X, Zerbib P, Tsicopoulos A, Geboes K, Bulois P, Breisse M, Vorng H, Gay J, Colombel JF, Desreumaux P, Chamaillard M.
INSERM, Lille, France.
Gut. 2006 Jun;55(6):815-23. Epub 2005 Nov 18.
More Articles...
- Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.
- PPARgamma as a new therapeutic target in inflammatory bowel diseases
- Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
- Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?
Copyright © 2008-2018 Intestinal Biotech Development